

June 11, 2025

iBody Initiates Collaborative Research with South Korea-Based CORbio  
on In Vitro Diagnostic Reagents

iBody Inc. (Head Office: Nagoya, Aichi, Japan; CEOs: Yo Max Amakusa and Shoji Ohuchi; hereinafter “iBody”) has launched a collaborative research project with CORbio Co., Ltd. (Head Office: Gyeonggi-do, South Korea; CEO: Bob Kim; hereinafter “CORbio”) to jointly develop in vitro diagnostic reagents.

Through this collaboration, iBody and CORbio—two innovative startups from Japan and South Korea—aim to generate technological and business synergies and promote the development of more effective and value-added in vitro diagnostic solutions.



Left: Bob Kim, CEO of CORbio / Right: Yo Max Amakusa, CEO of iBody

[About iBody]

iBody is a biotech startup founded in 2018 based on antibody expression technology developed by Professor Hideo Nakano of the Lab of Molecular Biotechnology, Graduate School of Bioagricultural Sciences, School of Agricultural Sciences, Nagoya University. The company's core technology, Ecobody®, enables rapid and comprehensive screening and expression of monoclonal antibodies directly from B cells isolated from small volumes of blood or tissues from humans, rabbits, alpacas, and other species. iBody conducts contract research and joint research for monoclonal antibody development. For more information, please visit our website: <https://www.ibody.co.jp/en/>

[About CORbio]

Established in 2023, CORbio is a bio-diagnostic company specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) devices for both human and veterinary applications. With a vision to become a leading innovator in the domestic and global IVD market through sustainable R&D and international partnerships, CORbio is currently focused on developing diagnostic devices for diabetes, inflammatory diseases, and liver conditions.



[Contact for this Release]

iBody Inc.

Administration Department

E-mail: [info@ibody.co.jp](mailto:info@ibody.co.jp)